Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Veracyte is a leading genomic diagnostics company that is fundamentally improving ...
Veracyte is a leading genomic diagnostics compa...
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
Abeona Therapeutics is focused on developing and delivering gene therapy products ...
Abeona Therapeutics is focused on developing an...
Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...
Iovance Biotherapeutics (formerly traded as Lio...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
Join the National Investor Network and get the latest information with your interests in mind.